

## 2015 Agenda

Thursday, May 14th

8:00am - 4:45pm Registration

8:00am - 9:30am Networking Breakfast

9:30am - 10:00am Welcome and Participant Introductions

10:00am - 10:45am What's changing: Dynamics of Building Great Life Sciences Companies in 2015

**Speakers:** 

Doug Cole MD, General Partner, Flagship Partners

Dan Lynch, Chairman, bluebird bio

Nancy Simonian MD, CEO, Syros Pharmaceuticals

**Moderator:** 

Jeff Jonker, President, NGM Biopharmaceuticals, Inc.

10:45am - 11:15am Networking Break

11:15am - 12:00pm AIR > Civitas > Acorda: 17 years in the Life of a Biotech Company

**Speakers:** 

Glenn Batchelder, Founder and Board Member,

**Civitas Therapeutics** 

Jim Wright, PhD, Co-Founder and Scientific Advisory Board Chairman, Civits

**Moderator:** 

Reid Leonard PhD, VP, Corporate Development, POTENZA Therapeutics

12:00pm - 1:30pm Lunch & Lunch Conversations

12:00pm - 1:30pm Lunch Discussion: Data Privacy and Cyber Security Issues

**Hosted by Foley & Lardner LLP** 

Speaker:

Seth Berman, Executive Managing Director, Stroz Friedberg

**Moderator:** 

Matthew Karlyn, Partner, Foley & Lardner LLP

1:30pm - 2:15pm Break-out conversations:

Genetics and Pharmacogenomics at Merck Research Labs Boston

Speaker:

Robert Plenge MD, PhD, Vice President, Head of Genetics & Pharmacogenomics

**Moderator:** 

Jeff Walsh, Chief Operating Officer, Bluebird Bio

Insights into the Changing VC Landscape

**Speakers:** 

**Brian Gallagher PhD**, Partner, SR One **Jason Rhodes**, Partner, Atlas Venture

**Moderator:** 

**Marian Nakada**, VP Venture Investments, Johnson & Johnson Development Corp.

Opportunities in Microbe-based Therapeutics

Speakers:

Jamie Heywood, Co-Founder, PatientsLikeMe; Chairman, AoBiome David Whitlock, Founding Scientist, AoBiome

**Moderator:** 

Robert Weisman, Life Sciences Reporter, the Boston Globe

2:15pm - 2:45pm Networking Break

2:45pm - 3:00pm Managing into the Clinical Stage

Speakers:

**Yamo Deniz MD**, Vice President, Rare Diseases, Global Medical Affairs, Genzyme **Tom Hughes PhD**, CEO, Zafgen

**Moderator:** 

Laurie Halloran, President and CEO, Halloran Consulting Group

3:30pm - 4:00pm Networking Break

4:00pm - 4:45pm Assembling Great Teams and Creating High-performance Cultures

**Speakers:** 

**Deborah Dunsire MD**, CEO, Forum Pharmaceuticals **Peter Hecht PhD**, CEO, Ironwood Pharmaceuticals

5:00pm - 6:30pm *Golf Workshop* 

5:00pm - 6:30pm *Bay Cruise* 

5:00pm - 7:00pm *Tennis Round Robin* 

7:00pm - 9:30pm **Clambake** 

Friday, May 15<sup>th</sup>

8:00am - 3:30pm Registration

8:00am - 9:00am Networking Breakfast

9:00am - 9:45am Is this a Bubble and if so What Would Pop It?

**Speakers:** 

Stelios Papadapoulos PhD, Chairman, Biogen Idec, Exelixis, Regulus

Therapeutics

Anna Protopapas, CEO, Mersana Therapeutics

9:45am - 10:15am Networking Break

10:15am - 11:15am Innovation & Cost Pressures in...

Drug Development and R&D

Speaker:

Kenneth Kaitin PhD, Professor and Director, Tufts Center for the Study of Drug

Development

**Moderator:** 

Alison Taunton-Rigby, PhD, OBE, Director & Trustee, Healthcare, Life Sciences

and Financial Services

Health Insurance and Healthcare Delivery

Speaker:

Eric Schultz, CEO, Harvard Pilgrim

**Moderator:** 

Colin Hill, CEO, GNS Healthcare

11:15am - 11:30am Networking Break

11:30am - 12:15pm Lunch & Lunch Conversations including:

Getting to the Clinic: Tips and Tricks for a Successful Ride!

**Hosted by:** 

Katie McCarthy, Managing Director, Halloran Consulting Group

12:15pm - 1:45pm Lunch Discussion: The New Disruptor

**Speakers:** 

Peter Lansbury PhD, CSO, Lysosomal Therapeutics

Robin Smith, CEO, Orig3n

**Moderator:** 

Steve Dickman, CEO, CBT Advisors

2:00pm - 2:45pm How Patients Will Find Trials, and How Trials Will Find Patients

Speakers:

Thomas Klein, CEO, Cytolon Gadi Lachman, CEO, TriNetX Martin Naley, CEO, Cure Forward

Moderator:

Alvin Shih MD, EVP of Research, Retrophin

2:45pm - 3:00pm Networking Break

3:00pm - 3:45pm What Virtual Means Today ve Technologies

Speaker:

Michael Gilman, PhD, CEO, Padlock Therapeutics

Werner Lanthaler PhD, CEO, Evotec